2016 | 2015 | Name | Country | 2016 | 2015 | 2016 | 2015 |
---|---|---|---|---|---|---|---|
1 | 4 | Pfizer | United States | $4,401M | $3,281M | AA+ | AA+ |
2 | 1 | Bayer | Germany | $4,365M | $4,746M | AAA- | AAA- |
3 | 3 | Novartis | Switzerland | $4,096M | $3,817M | AA | AAA- |
4 | 2 | Roche | Switzerland | $3,892M | $4,251M | AA+ | AAA- |
5 | 5 | Merck & Co | United States | $2,901M | $3,136M | AA | AAA- |
6 | 7 | Glaxosmithkline | United Kingdom | $2,781M | $2,890M | AA | AA+ |
7 | 6 | Sanofi | France | $2,704M | $3,062M | AA- | AA+ |
8 | 10 | Celgene | United States | $2,642M | $2,043M | AA- | AA- |
9 | 9 | Valeant Pharmace | Canada | $2,469M | $2,131M | A+ | AA- |
10 | 8 | Biogen | United States | $2,345M | $2,769M | AA | AA+ |